Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Eidos Therapeutics Inc (EIDX)

Eidos Therapeutics Inc (EIDX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,837,058
  • Shares Outstanding, K 38,537
  • Annual Sales, $ 26,690 K
  • Annual Income, $ -37,840 K
  • 60-Month Beta -0.26
  • Price/Sales 64.78
  • Price/Cash Flow N/A
  • Price/Book 9.89

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.61
  • Number of Estimates 3
  • High Estimate -0.58
  • Low Estimate -0.65
  • Prior Year -0.39
  • Growth Rate Est. (year over year) -56.41%

Price Performance

See More
Period Period Low Period High Performance
1-Month
42.38 +13.36%
on 06/29/20
53.38 -10.00%
on 06/09/20
-0.86 (-1.76%)
since 06/01/20
3-Month
38.24 +25.63%
on 05/14/20
54.90 -12.50%
on 04/28/20
+2.81 (+6.21%)
since 04/01/20
52-Week
28.00 +71.57%
on 08/05/19
66.56 -27.82%
on 12/16/19
+15.62 (+48.18%)
since 07/01/19

Most Recent Stories

More News
Eidos Therapeutics (EIDX) Looks Good: Stock Adds 6.4% in Session

Eidos Therapeutics (EIDX) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

EBS : 81.91 (+3.58%)
EIDX : 48.04 (+0.78%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Eidos Therapeutics, Inc. - EIDX

Pomerantz LLP is investigating claims on behalf of investors of Eidos Therapeutics, Inc. ("Eidos" or the "Company") (NASDAQ: EIDX).

EIDX : 48.04 (+0.78%)
Eidos Therapeutics Reports First Quarter 2020 Financial Results and Business Update

Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), today reported its financial results for the first quarter ended March 31, 2020 and provided an update on the company's operations.

EIDX : 48.04 (+0.78%)
Noteworthy Friday Option Activity: EIDX, PTCT, AMBA

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Eidos Therapeutics Inc , where a total volume of 2,106 contracts has been traded thus...

EIDX : 48.04 (+0.78%)
Why Eidos Therapeutics (EIDX) Stock Might be a Great Pick

Eidos Therapeutics (EIDX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

EIDX : 48.04 (+0.78%)
Eidos Therapeutics Reports Fourth Quarter and Year-End 2019 Financial Results and Business Update

Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), today reported its financial results for the fourth quarter and full year ended December 31, 2019 and provided an update on the company's recent achievements....

EIDX : 48.04 (+0.78%)
BridgeBio Pharma And Eidos Therapeutics To Present At Upcoming Investor Conferences

BridgeBio Pharma, Inc. (Nasdaq: BBIO), together with affiliate company Eidos Therapeutics (Nasdaq: EIDX) announced today that they are presenting at two upcoming investor conferences:

BBIO : 30.34 (-6.96%)
EIDX : 48.04 (+0.78%)
Vertex (VRTX) Hits 52-Week High, Can the Run Continue?

Vertex (VRTX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

VRTX : 286.28 (-1.39%)
GLPG : 202.44 (+2.61%)
VNDA : 11.93 (+4.28%)
EIDX : 48.04 (+0.78%)
Eidos Therapeutics, Inc. (EIDX) Moves to Buy: Rationale Behind the Upgrade

Eidos Therapeutics, Inc. (EIDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

EIDX : 48.04 (+0.78%)
CORRECTION: BridgeBio and Eidos Present Data from Phase 2 Open Label Extension Suggesting Long-term Tolerability of AG10 and Stabilization of Transthyretin Amyloid Cardiomyopathy Disease Measures

AG10 was Well Tolerated with Median 65 Weeks Follow-up since Phase 2 Initiation

BBIO : 30.34 (-6.96%)
EIDX : 48.04 (+0.78%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade EIDX with:

Business Summary

Eidos Therapeutics, Inc. is a clinical stage biopharmaceutical company. It discovers and develops novel oral therapy for the treatment of diseases caused by transthyretin amyloidosis. Eidos Therapeutics, Inc. is based in San Francisco, United States.

See More

Key Turning Points

2nd Resistance Point 50.89
1st Resistance Point 49.47
Last Price 48.04
1st Support Level 46.90
2nd Support Level 45.77

See More

52-Week High 66.56
Fibonacci 61.8% 51.83
Last Price 48.04
Fibonacci 50% 47.28
Fibonacci 38.2% 42.73
52-Week Low 28.00

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar